National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

amsacrine
An aminoacridine derivative with potential antineoplastic activity. Although its mechanism of action is incompletely defined, amsacrine may intercalate into DNA and inhibit topoisomerase II, resulting in DNA double-strand breaks, arrest of the S/G2 phase of the cell cycle, and cell death. This agent's cytotoxicity is maximal during the S phase of the cell cycle when topoisomerase levels are greatest. In addition, amsacrine may induce transcription of tumor promoter p53 protein and block p53 ubiquitination and proteasomal degradation, resulting in p53-dependent tumor cell apoptosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:acridinyl anisidide
Cain's Acridine
US brand name:Amsa P-D
Foreign brand names:Amekrin
Amsidine
Amsidyl
Lamasine
Abbreviations:AMSA
m-AMSA
Code names:CI-880
SN-11841
Chemical structure names:
  • 4'-(9-acridinylamino)methane-sulfon-m-anisidide
  • N-[4-(9-acridinylamino)-3-methoxyphenyl]methanesulfonamide



Previous:ampicillin sodium/sulbactam sodium, Ampligen, Amplimexon, amrubicin hydrochloride, Amsa P-D
Next:anakinra, anamorelin hydrochloride, anastrozole, anaxirone, Ancef

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov